Cabaletta Bio CABA 深 沪
已收盘 08-07 16:00:00 美东时间
2.79
+0.030
+1.09%
华盛通- 最 高2.82
- 今 开2.80
- 成交量 269.76万股
- 最 低 2.74
- 昨 收 2.76
- 总市值 4.55亿
- 52周最高 4.23
- 市盈率 静 --
- 换手率 1.65%
- 52周最低 1.40
- 委 比 85.04%
- 总股本 1.63亿
- 历史最高 26.35
- 量 比 0.69
- 振 幅 2.90%
- 历史最低 0.59
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cabaletta Bio Hits Reset on RESET-MS Trial, Narrowing Near-Term Upside in Multiple Sclerosis
Cabaletta Bio, Inc. ($CABA) announced an update on their ongoing clinical study...
06-26 00:30
Bending Spoons files for U.S. IPO
Bending Spoons, the parent company of AOL, Vimeo, and Eventbrite, has filed to go public in the U.S. with plans for an initial public offering this summer. The Milan-based tech company buys popular bu...
06-09 02:02
Cabaletta Bio Presents New Clinical Data Supporting Rese-Cel As Potential Treatment For Multiple Autoimmune Diseases, At EULAR 2026 Congress
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as
06-03 19:06
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Cabaletta Bio announced clinical data supporting rese-cel as a potential treatment for multiple autoimmune diseases, including myositis, systemic sclerosis, and lupus. Over 80% of Phase 1/2 dermatomyositis patients met the primary endpoint and maintained responses off immunomodulators for up to 1.5 years. The first juvenile dermatomyositis patient achieved a moderate response at 16 weeks, with response maintained at 32 weeks. Systemic sclerosis s...
06-03 11:00
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.
05-15 21:06
Cabaletta Bio Q1 EPS $(0.39), Inline
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same period last year.
05-14 19:23
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Cabaletta Bio announced new data from its RESET-PV trial showing that a single dose of PC-free rese-cel at the lowest dose level achieved compelling drug-free responses in 2 of 4 refractory pemphigus vulgaris patients. Translational data from the first two patients treated with rese-cel manufactured on the automated Cell Shuttle platform were consistent with previous findings. The company highlighted its focus on simplifying treatment regimens an...
05-14 11:00
美股牛股 | 多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%
多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%，获Long Lake以63亿美元收购>>
05-05 18:24
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
